Corticosteroids for Bacterial Meningitis in Adults in Sub-Saharan Africa
- 13 December 2007
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 357 (24), 2441-2450
- https://doi.org/10.1056/nejmoa065711
Abstract
In sub-Saharan Africa, bacterial meningitis is common and is associated with a high mortality. Adjuvant therapy with corticosteroids reduces mortality among adults in the developed world, but it has not been adequately tested in developing countries or in the context of advanced human immunodeficiency virus (HIV) infection. We conducted a randomized, double-blind, placebo-controlled trial of dexamethasone (16 mg twice daily for 4 days) and an open-label trial of intramuscular versus intravenous ceftriaxone (2 g twice daily for 10 days) in adults with an admission diagnosis of bacterial meningitis in Blantyre, Malawi. The primary outcome was death at 40 days after randomization. A total of 465 patients, 90% of whom were HIV-positive, were randomly assigned to receive dexamethasone (233 patients) or placebo (232 patients) plus intramuscular ceftriaxone (230 patients) or intravenous ceftriaxone (235 patients). There was no significant difference in mortality at 40 days in the corticosteroid group (129 of 231 patients) as compared with the placebo group (120 of 228 patients) by intention-to-treat analysis (odds ratio, 1.14; 95% confidence interval [CI], 0.79 to 1.64) or when the analysis was restricted to patients with proven pneumococcal meningitis (68 of 129 patients receiving corticosteroids vs. 72 of 143 patients receiving placebo) (odds ratio, 1.10; 95% CI, 0.68 to 1.77). There were no significant differences between groups in the outcomes of disability and death combined, hearing impairment, and adverse events. There was no difference in mortality with intravenous ceftriaxone (121 of 230 patients) as compared with intramuscular ceftriaxone (128 of 229 patients) (odds ratio, 0.88; 95% CI, 0.61 to 1.27). Adjuvant therapy with dexamethasone for bacterial meningitis in adults from an area with a high prevalence of HIV did not reduce mortality or morbidity. In this setting, intramuscular administration was not inferior to intravenous administration of ceftriaxone for bacterial meningitis. (Current Controlled Trials number, ISRCTN31371499.)This publication has 28 references indexed in Scilit:
- Practice Guidelines for the Management of Bacterial MeningitisClinical Infectious Diseases, 2004
- Corticosteroids for Everyone with Meningitis?New England Journal of Medicine, 2002
- Infectious Diseases: Considerations for the 21st CenturyClinical Infectious Diseases, 2001
- Bacterial Meningitis in Malawian Adults: Pneumococcal Disease is Common, Severe, and SeasonalClinical Infectious Diseases, 2000
- Dexamethasone as adjunctive therapy in bacterial meningitis. A meta-analysis of randomized clinical trials since 1988JAMA, 1997
- Pathogenesis of Pneumococcal InfectionNew England Journal of Medicine, 1995
- Ceftriaxone therapy of bacterial meningitisThe Pediatric Infectious Disease Journal, 1994
- Dexamethasone treatment for bacterial meningitis in children and adultsThe Pediatric Infectious Disease Journal, 1989
- Effects of Ampicillin and Corticosteroids on Brain Water Content, Cerebrospinal Fluid Pressure, and Cerebrospinal Fluid Lactate Levels in Experimental Pneumococcal MeningitisThe Journal of Infectious Diseases, 1985
- ASSESSMENT OF OUTCOME AFTER SEVERE BRAIN DAMAGE A Practical ScaleThe Lancet, 1975